Results 71 to 80 of about 11,369 (213)

Intratumoral Administration of Recombinant Murine Interleukin‐12 Prevents Tumor Progression and Bone Invasion

open access: yesOral Diseases, EarlyView.
ABSTRACT Objective Oral squamous cell carcinoma (OSCC) frequently invades the mandibular bone, leading to metastasis and poor prognosis. This study aimed to evaluate the therapeutic effects of locally administered interleukin‐12 (IL‐12) using an immunocompetent mouse model mimicking the clinical features of mandibular bone invasion. Methods The effects
Shun Kasahara   +11 more
wiley   +1 more source

Virotherapy – cancer targeted pharmacology

open access: yesDrug Discovery Today, 2012
Building on their success in vaccination, many groups are now exploring the use of viruses as anticancer agents. In general, viral therapeutics provide the possibility to express anticancer proteins directly at the tumour site, decreasing exposure to normal tissue during delivery and maximising therapeutic index.
Tedcastle, A   +4 more
openaire   +3 more sources

Oncolytic virotherapy and the current approaches in veterinary medicine

open access: yesGerman Journal of Veterinary Research, 2022
Cancer has an increasing incidence worldwide in humans and animals. In addition to traditional treatments such as surgery, radiotherapy, and chemotherapy, there is a search for new treatment strategies for cancer treatment.
Bengu Bilgic, Banu Dokuzeylul, Mehmet Or
doaj   +1 more source

Advanced Materials for Biologics Delivery to Brain Tumors

open access: yesAdvanced Materials, Volume 38, Issue 61, 2 November 2026.
Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng   +4 more
wiley   +1 more source

High Cell Density Cultivation of HEK293 Cells Using a 2L Membrane‐Stirred Bioreactor

open access: yesBiotechnology and Bioengineering, Volume 123, Issue 11, Page 3165-3174, November 2026.
ABSTRACT The use of perfusion systems for the continuous cultivation of animal cells at high cell density (HCD) for the production of recombinant proteins, viruses, and viral vectors has many advantages. Besides an enhancement of volumetric productivity and high cell viability, the product quality can be improved through a steady‐state environment ...
Lennart Jacobtorweihe   +5 more
wiley   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

open access: yesAdvanced Science, Volume 13, Issue 58, 19 October 2026.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao   +10 more
wiley   +1 more source

Targeting tumor vasculature through oncolytic virotherapy: recent advances

open access: yes, 2015
The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly increasing number of early- and late-stage clinical trials, some of them showing safety and promising therapeutic efficacy.
Merchan, Jaime R   +1 more
core   +1 more source

Oncolytic Virus‐Engineered Extracellular Vesicles Rewire Glioblastoma Immunity

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 10, October 2026.
ABSTRACT Immunotherapy with oncolytic Herpes simplex virus type 1 (oHSV‐1) shows promise for glioblastoma; however, clinical benefit remains uncommon due to tumour‐ and host‐mediated immunosuppression, which limits immune targeting of residual glioblastoma stem‐like cells (GSCs). To address this barrier, extracellular vesicles (EVs) harvested from oHSV‐
Klaudia Kiel   +18 more
wiley   +1 more source

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

open access: yesMolecular Therapy: Oncolytics, 2019
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng   +3 more
doaj   +1 more source

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

open access: yesSAGE Open Medical Case Reports, 2020
Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia.
Vladimirs Sorokins   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy